VivoSeq
Musculoskeletal

Cervical Ripening and Induction of Labor

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Cervical Ripening and Induction of Labor is an early-stage landscape with 0 programs across 2 companies. The most active players are Ferring, Regenex Pharmaceutical, China.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ferring logo

Ferring

0 programs

PreclinicalR

Regenex Pharmaceutical, China

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
Completed·Ferring logoFerring·Phase 2·NCT00828711·374 enrolled
Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
Completed·DDilafor AB·Phase 2·NCT04000438·365 enrolled
Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor
Completed·—·N/A·NCT01140971·180 enrolled
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
Completed·Ferring logoFerring·Phase 3·NCT00308711·1,308 enrolled
Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor
Completed·RRegenex Pharmaceutical, China·Phase 3·NCT01428037·225 enrolled
A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor
Terminated·MMilton S. Hershey Medical Center·Phase 4·NCT02777190·34 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)